XORTX Therapeutics Says Published Research Supports Company Approach to Gout Treatment
I'm PortAI, I can summarize articles.
XORTX Therapeutics announced that peer-reviewed research supports its gout treatment approach by inhibiting xanthine oxidase. The company plans a clinical trial for its oxypurinol formulation, moving towards a new drug application. CEO Allen Davidoff emphasized the potential for personalized therapy based on genetic predispositions. Additionally, XORTX is finalizing the acquisition of a renal anti-fibrotic program from Vectus Biosystems, expected to close by January 13. The board has been reduced to five members following recent resignations, with Krysta Davies Foss appointed as a new director.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments